– USA, CA – Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping solutions today announced the appointment of Dr. Aleks Rajkovic (MD, Ph.D.) to its board of directors.
About Dr. Aleks Rajkovic
Dr. Rajkovic is currently the Chief Genomics Officer at the University of California, San Francisco, a Stuart Lindsay Distinguished Professor in Experimental Pathology, and Medical Director and Chief of the Center for Genetic and Genomic Medicine at UCSF Health. Before arriving at UCSF, he was the Chief of Medical and Laboratory Genetics at the University of Pittsburgh Medical Center where he oversaw Pittsburgh’s cytogenomic, molecular genomic, and pregnancy screening laboratories as well as adult/cancer and prenatal genetic clinical services. He has been the Principal Investigator on NIH grants that studied various aspects of reproductive genomics, women’s health, and population genetic screening, and has published more than 150 original peer-reviewed articles in leading medical journals, including The New England Journal of Medicine, JAMA, and Nature Genetics.
“I am pleased to be joining Bionano’s board at this stage in the company’s development,” said Dr. Rajkovic. “I believe optical genome mapping can have a significant impact on patient management and research into novel genome-based biomarkers that could be therapeutically relevant and useful for patient recruitment and stratification.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services, and software. The Company offers OGM solutions for applications across basic, translational, and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation, and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view.
For more information: https://bionanogenomics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.